The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belyaev A.Yu.

Burdenko Neurosurgical Center

Usachev D.Yu.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Shults E.I.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Anaplastic astrocytoma and anaplastic oligodendroglioma of the brain: current state of the problem

Authors:

Belyaev A.Yu., Usachev D.Yu., Pronin I.N., Shults E.I., Batalov A.I.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2021;85(4): 96‑102

DOI: 10.17116/neiro20218504196

Read: 4247 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

ANAPLASTIC ASTROCYTOMA AND ANAPLASTIC OLIGODENDROGLIOMA OF THE BRAIN: CURRENT STATE OF THE PROBLEM
ANAPLASTIC ASTROCYTOMA AND ANAPLASTIC OLIGODENDROGLIOMA OF THE BRAIN: CURRENT STATE OF THE PROBLEM

To cite this article:

Belyaev AYu, Usachev DYu, Pronin IN, Shults EI, Batalov AI. Anaplastic astrocytoma and anaplastic oligodendroglioma of the brain: current state of the problem. Burdenko's Journal of Neurosurgery. 2021;85(4):96‑102. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20218504196

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
En plaque convexity hype­rostotic meni­ngioma: 69 cases from a singlecenter. Burdenko's Journal of Neurosurgery. 2025;(1):20-29
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Surgical access for thoracic and intrathoracic goiter. Piro­gov Russian Journal of Surgery. 2025;(1):54-61
Treatment of patients with exte­rnal inte­stinal fistulas and wide­spread peri­toneal adhe­sions. Piro­gov Russian Journal of Surgery. 2025;(2):44-49
Pregnancy in the «niche» of the scar on the uterus after cesa­rean section: the volu­mes of surgical treatment. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):37-43
Clinical effi­cacy and effect of neodymium laser on biomechanical properties of the vagi­nal wall in patients with grade I—II pelvic organ prolapse. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):50-58
Problems of pregnancy planning and gestation in patients with diffuse toxic goiter after radiotherapy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):82-87
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
Sepa­ration surgery in the treatment of spinal meta­stases. P.A. Herzen Journal of Onco­logy. 2025;(1):63-69
Surgical treatment of pulmonary tube­rculosis in children and adolescents. Piro­gov Russian Journal of Surgery. 2025;(3):16-23
Abstract:

This review is devoted to the problem of anaplastic cerebral gliomas. The authors consider classification, neuroimaging of these tumors including comparison of magnetic resonance imaging and positron emission tomography data. Clinical manifestations of anaplastic gliomas, issues of their histological and molecular genetic classification are discussed. Moreover, the authors compare the data of neuroimaging and genetic examinations of tumors. Other issues are multicomponent treatment and prognosis in patients with anaplastic glioma of the brain.

Keywords:

anaplastic astrocytoma
anaplastic oligodendroglioma
surgical treatment
radiotherapy
chemotherapy

Authors:

Belyaev A.Yu.

Burdenko Neurosurgical Center

Usachev D.Yu.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Shults E.I.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Received:

26.08.2020

Accepted:

28.05.2021

Close metadata

References:

  1. Wick W, Weller M. Classification and management of anaplastic gliomas. Current Opinion in Neurology. 2009;22(6):650-656.  https://doi.org/10.1097/WCO.0b013e3283329ce7
  2. Mechtler L. Neuroimaging in Neuro-Oncology. Neurologic Clinics. 2009;27(1):171-ix.  https://doi.org/10.1016/j.ncl.2008.09.015
  3. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 2006;129(Pt 7):1884-1891. https://doi.org/10.1093/brain/awl108
  4. Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: A TCGA/TCIA project. Clinical Cancer Research. 2017;23(20):6078-6085. https://doi.org/10.1158/1078-0432.CCR-17-0560
  5. Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, Shiga T, Hattori N, Tanaka S, Kuge Y, Tamaki N. Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(7):1071-1080. https://doi.org/10.1007/s00259-015-3046-1
  6. Gempt J, Bette S, Ryang YM, Buchmann N, Peschke P, Pyka T, Wester HJ, Förster S, Meyer B, Ringel F. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. European Journal of Radiology. 2015;84(5):955-962.  https://doi.org/10.1016/j.ejrad.2015.01.022
  7. Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Fujimoto Y, Kishima H, Kanemura Y, Nonaka M, Nakajima S, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. Diagnostic and prognostic value of 11C-methionine PET for nonenhancing gliomas. American Journal of Neuroradiology. 2016;37(1):44-50.  https://doi.org/10.3174/ajnr.A4460
  8. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. Journal of Nuclear Medicine. 2013;54(2):229-235.  https://doi.org/10.2967/jnumed.112.109603
  9. Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R, Capelle L, Guillevin R, Foehrenbach H, Buvat I. Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT. Clinical Nuclear Medicine. 2013;38(2):81-87.  https://doi.org/10.1097/RLU.0b013e318279fd5a
  10. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803-820.  https://doi.org/10.1007/s00401-016-1545-1
  11. van den Bent MJ, Bromberg JE. Anaplastic oligodendroglial tumors. Handbook of Clinical Neurology. 2012;105:467-484.  https://doi.org/10.1016/B978-0-444-53502-3.00003-3
  12. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. Journal of Neuropathology and Experimental Neurology. 2007;66(6):545-551.  https://doi.org/10.1097/01.jnen.0000263869.84188.72
  13. Van Den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician’s perspective. Acta Neuropathologica. 2010;120(3):297-304.  https://doi.org/10.1007/s00401-010-0725-7
  14. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathologica. 2010;120(6):707-718.  https://doi.org/10.1007/s00401-010-0781-z
  15. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, Von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology. 2009;27(35):5874-5880. https://doi.org/10.1200/JCO.2009.23.6497
  16. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology. 2013;31(3):344-350.  https://doi.org/10.1200/JCO.2012.43.2229
  17. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A.Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent Oligodendrogliomas. Journal of Neuropathology and Experimental Neurology. 2004;63(4):314-322.  https://doi.org/10.1093/jnen/63.4.314
  18. Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. Journal of Neuro-Oncology. 2015;124(2):197-205.  https://doi.org/10.1007/s11060-015-1822-1
  19. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet Oncology. 2014;15(9):395-403.  https://doi.org/10.1016/S1470-2045(14)70011-7
  20. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Annals of Neurology. 2005;57(6):855-865.  https://doi.org/10.1002/ana.20496
  21. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-1018. https://doi.org/10.1016/S0140-6736(02)08091-1
  22. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council Trial. Journal of Clinical Oncology. 2001;19(2):509-518.  https://doi.org/10.1200/JCO.2001.19.2.509
  23. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515-1522. https://doi.org/10.1212/WNL.0b013e3182a95680
  24. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research. 2008;14(21):7068-7073. https://doi.org/10.1158/1078-0432.CCR-08-0260
  25. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. Journal of Clinical Oncology. 2013;31(3):337-343.  https://doi.org/10.1200/JCO.2012.43.2674
  26. Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. Journal of Clinical Oncology. 2010;28(30):4601-4608. https://doi.org/10.1200/JCO.2009.27.1932
  27. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study. British Journal of Cancer. 2009;101(12):1986-1994. https://doi.org/10.1038/sj.bjc.6605412
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.